Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Prognosticators and the role of lymphadenectomy in uterine leiomyosarcomas.

Ayhan A, Aksan G, Gultekin M, Esin S, Himmetoglu C, Dursun P, Usubutun A, Yuce K.

Arch Gynecol Obstet. 2009 Jul;280(1):79-85. doi: 10.1007/s00404-008-0876-0. Epub 2008 Dec 19.

PMID:
19096861
2.

Does Lymphadenectomy Improve Survival in Uterine Leiomyosarcoma?

Tasci T, Karalok A, Taskin S, Ureyen I, Kımyon G, Tulek F, Ozfuttu A, Turan T, Tulunay G, Kose MF, Ortac F.

Int J Gynecol Cancer. 2015 Jul;25(6):1031-6. doi: 10.1097/IGC.0000000000000452.

PMID:
25853382
3.
4.

The impact of tumor morcellation during surgery on the prognosis of patients with apparently early uterine leiomyosarcoma.

Park JY, Park SK, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH.

Gynecol Oncol. 2011 Aug;122(2):255-9. doi: 10.1016/j.ygyno.2011.04.021. Epub 2011 May 12.

PMID:
21565389
5.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
6.

Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis.

Nemani D, Mitra N, Guo M, Lin L.

Gynecol Oncol. 2008 Oct;111(1):82-8. doi: 10.1016/j.ygyno.2008.05.016.

PMID:
18674808
7.

Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy.

Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P.

Eur Urol. 2009 May;55(5):1003-11. doi: 10.1016/j.eururo.2009.01.046. Epub 2009 Feb 4.

PMID:
19211184
8.

Extent of lymphadenectomy and outcome for patients with stage I nonsmall cell lung cancer.

Varlotto JM, Recht A, Nikolov M, Flickinger JC, Decamp MM.

Cancer. 2009 Feb 15;115(4):851-8. doi: 10.1002/cncr.23985.

9.

Leiomyosarcoma: a 45-year review at Charity Hospital, New Orleans.

Hill MA, Mera R, Levine EA.

Am Surg. 1998 Jan;64(1):53-60; discussion 60-1.

PMID:
9457038
10.

lymph node ratio as a prognostic factor in patients with stage III rectal cancer treated with total mesorectal excision followed by chemoradiotherapy.

Kim YS, Kim JH, Yoon SM, Choi EK, Ahn SD, Lee SW, Kim JC, Yu CS, Kim HC, Kim TW, Chang HM.

Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):796-802. doi: 10.1016/j.ijrobp.2008.08.065. Epub 2009 Mar 14.

PMID:
19289261
11.

Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.

Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB.

Histopathology. 2009 Feb;54(3):355-64. doi: 10.1111/j.1365-2559.2009.03231.x.

PMID:
19236512
12.
13.

Uterine papillary serous carcinoma: patterns of failure and survival.

Wang W, DO V, Hogg R, Wain G, Brand A, Bull C, Stenlake A, Gebski V.

Aust N Z J Obstet Gynaecol. 2009 Aug;49(4):419-25. doi: 10.1111/j.1479-828X.2009.01016.x.

PMID:
19694700
14.

Extent of pelvic lymphadenectomy in women with squamous cell carcinoma of the uterine cervix: is there any prognostic value?

Fregnani JH, de Oliveira Latorre Mdo R, Novik PR, Lopes A, de Oliveira JC, Tsunoda AT, Soares FA.

J Surg Oncol. 2009 Sep 1;100(3):252-7. doi: 10.1002/jso.21252.

PMID:
19235781
15.

Clinicopathological features and prognostic factors of the uterine sarcomas: 20 years of experience at Cukurova University.

Khatib G, Guzel AB, Gulec UK, Gumurdulu D, Vardar MA, Altintas A.

Eur J Gynaecol Oncol. 2014;35(6):646-54.

PMID:
25556269
16.

Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer.

Demir A, Turna A, Kocaturk C, Gunluoglu MZ, Aydogmus U, Urer N, Bedirhan MA, Gurses A, Dincer SI.

Ann Thorac Surg. 2009 Apr;87(4):1014-22. doi: 10.1016/j.athoracsur.2008.12.053.

PMID:
19324121
17.

Surgical cytoreduction in patients with metastatic uterine leiomyosarcoma at the time of initial diagnosis.

Leitao MM Jr, Zivanovic O, Chi DS, Hensley ML, O'Cearbhaill R, Soslow RA, Barakat RR.

Gynecol Oncol. 2012 May;125(2):409-13. doi: 10.1016/j.ygyno.2012.02.014. Epub 2012 Feb 21.

PMID:
22366592
18.

Prognostic factors in early-stage leiomyosarcoma of the uterus.

Pelmus M, Penault-Llorca F, Guillou L, Collin F, Bertrand G, Trassard M, Leroux A, Floquet A, Stoeckle E, Thomas L, MacGrogan G.

Int J Gynecol Cancer. 2009 Apr;19(3):385-90. doi: 10.1111/IGC.0b013e3181a1bfbc.

PMID:
19407564
19.

Clinical outcome affected by tumor morcellation in unexpected early uterine leiomyosarcoma.

Lin KH, Torng PL, Tsai KH, Shih HJ, Chen CL.

Taiwan J Obstet Gynecol. 2015 Apr;54(2):172-7. doi: 10.1016/j.tjog.2015.03.001.

20.

Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior.

Giuntoli RL 2nd, Gostout BS, DiMarco CS, Metzinger DS, Keeney GL.

J Reprod Med. 2007 Nov;52(11):1001-10.

PMID:
18161397

Supplemental Content

Support Center